IDEAYA Biosciences (NASDAQ:IDYA) Announces Earnings Results, Beats Estimates By $0.03 EPS

IDEAYA Biosciences (NASDAQ:IDYA) announced its quarterly earnings results on Monday. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.03, Briefing.com reports. During the same period last year, the company posted ($0.46) EPS.

IDEAYA Biosciences Trading Down 1.4 %

IDYA stock traded down $0.44 during midday trading on Thursday, hitting $29.97. The stock had a trading volume of 122,005 shares, compared to its average volume of 849,378. The business has a fifty day moving average price of $32.57 and a two-hundred day moving average price of $36.79. IDEAYA Biosciences has a 1-year low of $27.52 and a 1-year high of $47.74. The firm has a market cap of $2.53 billion, a P/E ratio of -13.05 and a beta of 0.86.

Analysts Set New Price Targets

IDYA has been the subject of several research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Leerink Partnrs lowered shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Lifesci Capital raised IDEAYA Biosciences to a “strong-buy” rating in a report on Monday, July 29th. Citigroup lowered their price objective on IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a research report on Tuesday, August 27th. Finally, Stifel Nicolaus raised their price target on shares of IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, IDEAYA Biosciences currently has an average rating of “Moderate Buy” and an average price target of $53.08.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.